<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00695435</url>
  </required_header>
  <id_info>
    <org_study_id>C-08-33</org_study_id>
    <nct_id>NCT00695435</nct_id>
  </id_info>
  <brief_title>Tobramycin Tear Concentrations</brief_title>
  <official_title>Evaluation of Tobramycin Tear Concentrations of TOBRADEX® Ophthalmic Suspension, Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension Versus TOBREX® Ophthalmic Solution in Normal Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Alcon Research</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Alcon Research</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the Tobramycin tear concentration values of TOBRADEX® Ophthalmic Suspension,
      Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension versus TOBREX® Ophthalmic
      Solution in normal volunteers.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2008</start_date>
  <primary_completion_date type="Actual">June 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tobramycin Tear Concentration Cmax (Maximum Concentration)</measure>
    <time_frame>2, 4, 6, 12, and 18 minutes</time_frame>
    <description>Tear samples were collected to measure tobramycin concentrations at 2, 4, 6, 12, and 18 minutes post-drop instillation in each subject's right eye for each treatment period.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tobramycin Tear Concentration Area Under the Curve (AUC)</measure>
    <time_frame>2 to 18 minutes post administration</time_frame>
    <description>Trapezoidal AUC was calculated from 2 to 18 minutes.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Dry Eye</condition>
  <arm_group>
    <arm_group_label>Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TOBREX® Ophthalmic Solution</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TOBREX® Ophthalmic Solution</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TOBRADEX® Ophthalmic Suspension</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>TOBRADEX® Ophthalmic Suspension</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOBRADEX Ophthalmic Suspension</intervention_name>
    <description>TOBRADEX Ophthalmic Suspension 1 drop each eye at baseline</description>
    <arm_group_label>TOBRADEX® Ophthalmic Suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension</intervention_name>
    <description>Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension 1 drop each eye at baseline</description>
    <arm_group_label>Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TOBREX Ophthalmic Solution</intervention_name>
    <description>TOBREX Ophthalmic Solution 1 drop each eye at baseline</description>
    <arm_group_label>TOBREX® Ophthalmic Solution</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

          -  Visual Acuity (VA) of 0.6 logMAR or better

          -  Tear meniscus height of ≥ 0.3mm at Visit 1.

          -  No concomitant topical ocular medications, including artificial tears, during the
             study period

        Exclusion

          -  ocular hypertension, iritis or uveitis, glaucoma

          -  ocular surgery, intraocular surgery or ocular laser procedures in either eye within
             the past six months

          -  epithelial herpes simplex (dendritic keratitis); Vaccinia, active or recent varicella
             viral disease of the cornea and/or conjunctiva; ocular Rosacea; Mycobacterial
             infection of the eye; and / or fungal disease of the eye

          -  lacrimal duct obstruction, dry eye, ocular allergies.

          -  contact lens within 7 days of Visit 1.

          -  ocular medications within 14 days of Visit 1.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Contact Alcon Call Center For Trial Locations</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76134</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 9, 2008</study_first_submitted>
  <study_first_submitted_qc>June 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 11, 2008</study_first_posted>
  <results_first_submitted>April 27, 2009</results_first_submitted>
  <results_first_submitted_qc>January 15, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">February 5, 2010</results_first_posted>
  <last_update_submitted>February 23, 2010</last_update_submitted>
  <last_update_submitted_qc>February 23, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2010</last_update_posted>
  <responsible_party>
    <name_title>Michael Brubaker</name_title>
    <organization>Alcon</organization>
  </responsible_party>
  <keyword>normal volunteers</keyword>
  <keyword>anti-infective</keyword>
  <keyword>tobramycin</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Dexamethasone acetate</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>BB 1101</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
    <mesh_term>Tobramycin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Randomized, single center (Alcon Eye Clinic),</recruitment_details>
      <pre_assignment_details>Treatment randomization schedules were generated and maintained by the Alcon SAS Programming group. Only when the data were verified and validated and the database locked were the appropriate personnel unmasked.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>TOBRADEX, Then Tob 0.3%/Dex 0.05%, Then TOBREX</title>
          <description>Patients received TOBRADEX first, then Tob 0.3%/Dex 0.05%, then TOBREX</description>
        </group>
        <group group_id="P2">
          <title>Tob 0.3%/Dex 0.05%, Then TOBREX, Then TOBRADEX</title>
          <description>Patients received Tob 0.3%/Dex 0.05% first, then TOBREX, then TOBRADEX</description>
        </group>
        <group group_id="P3">
          <title>TOBREX, Then TOBRADEX, Then Tob 0.3%/Dex 0.05%</title>
          <description>Patients received TOBREX first, then TOBRADEX, then Tob 0.3%/Dex 0.05%</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Overall Study</title>
          <description>Overall Study</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="21"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Tobramycin Tear Concentration Cmax (Maximum Concentration)</title>
        <description>Tear samples were collected to measure tobramycin concentrations at 2, 4, 6, 12, and 18 minutes post-drop instillation in each subject’s right eye for each treatment period.</description>
        <time_frame>2, 4, 6, 12, and 18 minutes</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension</title>
            <description>Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension</description>
          </group>
          <group group_id="O2">
            <title>TOBREX® Ophthalmic Solution</title>
            <description>TOBREX® Ophthalmic Solution</description>
          </group>
          <group group_id="O3">
            <title>TOBRADEX® Ophthalmic Suspension</title>
            <description>TOBRADEX® Ophthalmic Suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Tobramycin Tear Concentration Cmax (Maximum Concentration)</title>
          <description>Tear samples were collected to measure tobramycin concentrations at 2, 4, 6, 12, and 18 minutes post-drop instillation in each subject’s right eye for each treatment period.</description>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="853" spread="618"/>
                    <measurement group_id="O2" value="527" spread="428"/>
                    <measurement group_id="O3" value="542" spread="425"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Tobramycin Tear Concentration Area Under the Curve (AUC)</title>
        <description>Trapezoidal AUC was calculated from 2 to 18 minutes.</description>
        <time_frame>2 to 18 minutes post administration</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension</title>
            <description>Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension</description>
          </group>
          <group group_id="O2">
            <title>TOBREX® Ophthalmic Solution</title>
            <description>TOBREX® Ophthalmic Solution</description>
          </group>
          <group group_id="O3">
            <title>TOBRADEX® Ophthalmic Suspension</title>
            <description>TOBRADEX® Ophthalmic Suspension</description>
          </group>
        </group_list>
        <measure>
          <title>Tobramycin Tear Concentration Area Under the Curve (AUC)</title>
          <description>Trapezoidal AUC was calculated from 2 to 18 minutes.</description>
          <units>min*ug/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="21"/>
                <count group_id="O2" value="21"/>
                <count group_id="O3" value="21"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6124" spread="4776"/>
                    <measurement group_id="O2" value="2119" spread="1820"/>
                    <measurement group_id="O3" value="2484" spread="2182"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension</title>
          <description>Tobramycin 0.3% / Dexamethasone 0.05% Ophthalmic Suspension</description>
        </group>
        <group group_id="E2">
          <title>TOBREX®</title>
          <description>TOBREX® Ophthalmic Solution</description>
        </group>
        <group group_id="E3">
          <title>TOBRADEX®</title>
          <description>TOBRADEX® Ophthalmic Suspension</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Dry Eye</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="21"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="21"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Alcon Clinical</name_or_title>
      <organization>Alcon Research, LTD</organization>
      <phone>888.451.3937; 817.568.6725</phone>
      <email>medinfo@alconlabs.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

